Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu University, Gifu, Japan.
Department of Pediatric Surgery, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan.
Pediatr Blood Cancer. 2019 Sep;66(9):e27878. doi: 10.1002/pbc.27878. Epub 2019 Jun 17.
Kaposiform lymphangiomatosis (KLA) has recently been distinguished as a novel subtype of generalized lymphatic anomaly (GLA), and is characterized by foci of spindle endothelial cells amid a background of malformed lymphatic channels. The etiology of these diseases remains unknown and diagnosis is confounded by their similar clinical findings. This study aimed to clarify differences in the clinical findings and plasma cytokine profiles of GLA and KLA patients.
Clinical features data of GLA and KLA patients were obtained from a national survey. Differences in clinical findings, plasma levels of cytokines, and survival were analyzed. Plasma was obtained from healthy controls and GLA and KLA patients. Thirty-six angiogenic and lymphangiogenic factors were evaluated for cytokine concentration.
Twenty-one patients with GLA and 11 with KLA were recruited. Mediastinal masses, hemorrhagic pericardial and pleural effusion, coagulation disorders, and thrombocytopenia were more frequent in KLA than in GLA. KLA had a significantly poorer outcome than GLA (P = 0.044). Soluble VEGFR3, angiopoietin 2, HGF, soluble HER2, tenascin C, and soluble HGFR levels were higher in KLA. Notably, soluble VEGFR3 and angiopoietin 2 levels were approximately 10-fold higher than those of other molecules measured. However, soluble VEGFR1 and soluble TIE2 were lower in KLA than in GLA and the controls.
Patients with KLA have an unfavorable prognosis and serious symptoms (hemorrhagic pleural effusion and coagulation disorders). Our data indicate that eight angiogenic cytokines might be potential biomarkers of KLA.
卡波西样淋巴管瘤病(KLA)最近被确定为一种新的全身性淋巴管异常(GLA)亚型,其特征是梭形内皮细胞灶位于畸形淋巴管背景中。这些疾病的病因尚不清楚,由于其临床表现相似,诊断较为困难。本研究旨在阐明 GLA 和 KLA 患者在临床发现和血浆细胞因子谱方面的差异。
从全国性调查中获得了 GLA 和 KLA 患者的临床特征数据。分析了临床发现、血浆细胞因子水平和生存的差异。从健康对照者和 GLA 和 KLA 患者中采集血浆。评估了 36 种血管生成和淋巴管生成因子的细胞因子浓度。
共纳入 21 例 GLA 患者和 11 例 KLA 患者。与 GLA 相比,KLA 更常出现纵隔肿块、出血性心包和胸腔积液、凝血障碍和血小板减少。KLA 的预后明显比 GLA 差(P=0.044)。KLA 患者的可溶性 VEGFR3、血管生成素 2、HGF、可溶性 HER2、腱蛋白 C 和可溶性 HGFR 水平较高。值得注意的是,可溶性 VEGFR3 和血管生成素 2 的水平比其他测量的分子高约 10 倍。然而,KLA 患者的可溶性 VEGFR1 和可溶性 TIE2 水平低于 GLA 和对照组。
KLA 患者预后不良,症状严重(胸腔出血和凝血障碍)。我们的数据表明,八种血管生成细胞因子可能是 KLA 的潜在生物标志物。